Please use this identifier to cite or link to this item: https://dora.health.qld.gov.au/qldresearchjspui/handle/1/2037
Full metadata record
DC FieldValueLanguage
dc.contributor.authorWallis, M.en
dc.contributor.authorChristodoulou, J.en
dc.contributor.authorWools, C.en
dc.contributor.authorWelch, A.en
dc.contributor.authorThorburn, D.en
dc.contributor.authorBaker, N.en
dc.contributor.authorBalasubramaniam, S.en
dc.contributor.authorBratkovic, D.en
dc.contributor.authorComan, D.en
dc.contributor.authorCompton, A.en
dc.contributor.authorDelatycki, M.en
dc.contributor.authorEllaway, C.en
dc.contributor.authorFahey, M.en
dc.contributor.authorFletcher, J.en
dc.contributor.authorFrazier, A.en
dc.contributor.authorGhaoui, R.en
dc.contributor.authorGoel, H.en
dc.contributor.authorHock, D.en
dc.contributor.authorKava, M.en
dc.contributor.authorLake, N.en
dc.contributor.authorLamont, P.en
dc.contributor.authorLee, J.en
dc.contributor.authorPanetta, J.en
dc.contributor.authorPhillips, L.en
dc.contributor.authorRius, R.en
dc.contributor.authorRyan, M.en
dc.contributor.authorSmith, N.en
dc.contributor.authorStroud, D.en
dc.contributor.authorTchan, M.en
dc.contributor.authorWalsh, M.en
dc.date.accessioned2022-11-07T23:27:16Z-
dc.date.available2022-11-07T23:27:16Z-
dc.date.issued2020en
dc.identifier.citation28, (SUPPL 1), 2020, p. 55-56en
dc.identifier.otherRISen
dc.identifier.urihttp://dora.health.qld.gov.au/qldresearchjspui/handle/1/2037-
dc.description.abstractIntroduction: The Australian Genomics Health Alliance is a nationally funded health services research project focused on bringing genomic technologies to the clinic. The Mitochondrial Disease (MD) Flagship brings together expert clinicians from around Australia, specialist diagnostic laboratories and researchers expert in functional characterization of MD to examine the clinical utility of genomic sequencing for efficient diagnosis of MD. Methods: We recruited 134 paediatric and adult individuals with a probable or definite MD diagnosis, based on modified Nijmegen criteria. Their blood DNA was randomized to either whole genome sequencing or whole exome plus mitochondrial DNA sequencing. Results: Our definitive diagnostic yield is currently ~36% for both whole genome and whole exome/mitochondrial DNA approaches, with most diagnosed cases having a primary defect in the nuclear genome. Not surprisingly, 14% of individuals with confirmed molecular diagnoses had mutations in non-MD genes, reflecting phenotypic overlap. Unsolved patients have been triaged to one or more targeted functional tests, quantitative proteomics, RNAseq or long-read genome sequencing. This enabled re-categorising of numerous class 3 variants and identification of novel disease genes and mechanisms, including a de novo duplication within the ATAD3 locus resulting in a presumably toxic fusion protein (see Frazier et al. abstract). Conclusions: Our collaborative effort has demonstrated that using a consistent national approach for clinically triaging cases for genomic sequencing is both effective and efficient, usually obviates the need for invasive biopsies and in some cases enables targeted therapies.L6340692602021-02-08 <br />en
dc.language.isoenen
dc.relation.ispartofEuropean Journal of Human Geneticsen
dc.titleThe Australian Genomic Health Alliance Mitochondrial Flagship-A national approach to genomic diagnosticsen
dc.typeArticleen
dc.identifier.doi10.1038/s41431-020-00740-6en
dc.subject.keywordsDNA sequencingen
dc.subject.keywordsexomeen
dc.subject.keywordsfemaleen
dc.subject.keywordshumanen
dc.subject.keywordsmaleen
dc.subject.keywordsmolecular diagnosisen
dc.subject.keywordsmolecularly targeted therapyen
dc.subject.keywordsproteomicsen
dc.subject.keywordsconference abstracten
dc.subject.keywordschilden
dc.subject.keywordscontrolled studyen
dc.subject.keywordsadulten
dc.subject.keywordsquantitative analysisen
dc.subject.keywordsrandomized controlled trialen
dc.subject.keywordsRNA sequencingen
dc.subject.keywordsside effecten
dc.subject.keywordswhole genome sequencingen
dc.subject.keywordsfusion proteinmitochondrial DNAen
dc.subject.keywordsadverse drug reactionen
dc.subject.keywordsdiagnosisen
dc.subject.keywordsdiagnostic valueen
dc.subject.keywordsdisorders of mitochondrial functionsen
dc.relation.urlhttps://www.embase.com/search/results?subaction=viewrecord&id=L634069260&from=exporthttp://dx.doi.org/10.1038/s41431-020-00740-6 |en
dc.identifier.risid2507en
dc.description.pages55-56en
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
item.fulltextNo Fulltext-
item.grantfulltextnone-
item.openairetypeArticle-
item.languageiso639-1en-
Appears in Sites:Children's Health Queensland Publications
Show simple item record

Page view(s)

70
checked on Apr 17, 2025

Google ScholarTM

Check

Altmetric


Items in DORA are protected by copyright, with all rights reserved, unless otherwise indicated.